The National Institute of Allergy and Infectious Diseases (NIAID) is competing a support contract for scientific, professional and technical expertise for NIAID’s research programs. NIAID conducts and supports basic and applied research [Read more]
See what we’re reading this week at Global Biodefense on topics including a National Academies’ report on Dual Use Research of Concern, antibody therapeutics for ricinosis, and questions on inhaled flu vaccine [Read more]
Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV) is one of the most promising candidates against the Ebola virus. In phase I of the clinical trial in 2016, it proved to be a [Read more]
Two Johns Hopkins materials science graduate students and their professors played a key role in a multi-institution research project that pinpointed how a tiny protein seems to make the deadly Ebola virus [Read more]
Tulane University researchers and collaborators have discovered a new biological activity in a small protein from the deadly Ebola virus. A compound known as the “delta peptide” is produced in large amounts [Read more]
Researchers from the University of Liverpool have conducted a study of Ebola survivors to determine if the virus has any specific effects on the back on the eye. Using an ultra widefield [Read more]
The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Virology Division, Pathogenesis and Immunology Branch has been tasked by the Defense Threat Reduction Agency to investigate a potential for enhanced efficacy [Read more]
Pacific Northwest National Laboratory scientists were recently recognized by the Secretary of the Department of Energy (DOE) for their role helping to stem the Ebola epidemic in West Africa two years ago. [Read more]
John Kash, researcher from the National Institute of Allergy and Infectious Disease (NIAID) Viral Pathogenesis and Evolution Section, with his colleagues, carefully tracked changes in gene expression that occurred in a 34-year-old [Read more]
The Biomedical Advanced Research and Development Authority (BARDA) has issued two pre-solicitation notices supporting mid- and late-phase development of medical countermeasures for Ebola Virus Disease (EVD). There are currently no vaccines or therapeutics [Read more]
© 2017 Global Biodefense